Compound ID | 3299

Update compound information

Meropenem + pralurbactam

Class: Beta-lactam + beta-lactamase inhibitor

Agent Type: Semisynthetic; Small molecule; Direct acting; Indirect acting; Antibiotic adjuvant;
Spectrum of activity: Gram-negative
Mechanism of action: Cell wall synthesis inhibitor
Target Pathogen: Active against complicated intra-abdominal infections
Combined with other compounds: Yes
Description: Semi-synthetic compound (meropenem) and synthetic compound (pralurbactam); drug combination
Institute where first reported: Qilu Pharmaceutical Co., Ltd.
Year first mentioned: 2023
Highest development stage: Phase 3 (NCT06633718)
Development status: Active (as of 2024)
Chemical structure(s):
Click here for structure editor
Molecular weight: 383.46
Iso. SMILES: C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O
InChI Key: DMJNNHOOLUXYBV-PQTSNVLCSA-N
Can. SMILES: C[C@@H]1[C@@H]2[C@@H]([C@@H](C)O)C(=O)N2C(=C1S[C@H]3C[C@@H](C(=O)N(C)C)NC3)C(=O)O
InChI: InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/441130
Citation: https://clinicaltrials.gov/study/NCT06633718?term=pralurbactam&rank=1

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.